|
WO2021068068A1
|
|
Chimeric cytokine receptors
|
|
WO2020252598A1
|
|
Radiolabeled compounds targeting the prostate-specific membrane antigen
|
|
WO2020237368A1
|
|
Immunotherapy constructs targeting kras antigens
|
|
WO2020210919A1
|
|
Novel radiolabelled cxcr4-targeting compounds for diagnosis and therapy
|
|
WO2020210909A1
|
|
Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer
|
|
WO2020163953A1
|
|
Compositions and methods for enhanced lymphocyte-mediated immunotherapy
|
|
WO2020124237A1
|
|
Dual mode 18f-labelled theranostic compounds and uses thereof
|
|
WO2020118427A1
|
|
Antimicrobial peptides
|
|
WO2020107121A1
|
|
Motion synchronized arc radiotherapy
|
|
WO2020102912A1
|
|
Volumetric multi-modal microscopy methods and systems
|
|
WO2021068051A1
|
|
Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
|
|
WO2020079591A1
|
|
Gene expression profiles for b-cell lymphoma and uses thereof
|
|
WO2021050059A1
|
|
Dna-pk inhibiting compounds
|
|
WO2020047660A1
|
|
Image guided micro-raman spectroscopy
|
|
CA3100868A1
|
|
Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy
|
|
CA3086931A1
|
|
Endoscopic raman spectroscopy device
|
|
EP3717660A1
|
|
Methods for evaluating head and neck cancers
|
|
GB201817342D0
|
|
Compounds
|
|
CA3053825A1
|
|
Apparatus for positioning a breast for radiation treatment
|
